Close Menu

Cenix BioScience

The company was founded in 1999 to provide high-throughput target discovery and validation services for academic and industry partners.

NEW YORK (GenomeWeb) – Contract research organization Cenix BioScience this week announced a research framework agreement with metabolite services and biomarker firm Metanomics Health.

NEW YORK (GenomeWeb) – Cenix BioScience this week announced it has signed an agreement to provide target-validation services to BASF company Metanomics.

NEW YORK (GenomeWeb) – Cenix Biosciences this week announced that it has signed an agreement to provide RNAi-based high-content screening services to Germany's Bayer Pharma.

NEW YORK (GenomeWeb News) – Cenix BioScience and Debiopharm Group today announced a research agreement to use Cenix's technology in support of Debiopharm's drug development efforts.

Cenix BioScience this week announced that it has signed an agreement to provide its research services to Swiss drugmaker Debiopharm.

Cenix BioScience said this week that its roughly one-year old service contract with Ugichem, a developer of novel gene-silencing therapeutics, has been extended.

As part of an ongoing effort to support research into rare and neglected diseases, Cenix BioScience announced last week that it has struck a research agreement with the Children's Tumor Foundation, a non-profit organization focused on developing treatments for neurofibromatosis.

Cytoo will coordinate a new European consortium that will rely on the firm's micropattern array platform to develop a high-throughput approach to RNAi screening in cultured cells.

Pages

The Lancet has made changes to its peer-review process in response to its recent retraction of a COVID-19-related paper, Science reports.

The New York Times reports that a series of emails show how Department of Health and Human Services officials sought to silence the Centers for Disease Control and Prevention.

A new initiative aims to move Australia's genome sequencing labs onto one system, the Sydney Morning Herald reports.

In PLOS this week: recessive mutation tied to early-onset dilated cardiomyopathy, epigenetic analysis of lung adenocarcinoma, and more.